Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Akebia Therapeutics, Inc. (AKBA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/10/2020 |
GN
| INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Akebia Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims. |
| 03/27/2019 |
GN
| Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy — Fundamental Analysis, Key Performance Indications |
| 11/29/2018 |
GN
| ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics |
| 10/30/2018 |
GN
| Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger with Akebia Therapeutics |
| 07/06/2018 |
GN
| INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. is Fair to Shareholders |
| 06/06/2018 |
GN
| Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic Software Enterprises, Jounce Therapeutics, and Akebia Therapeutics — Discovering Underlying Factors of Influence |
| 04/09/2018 |
GN
| Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement |
| 03/16/2018 |
GN
| New Research: Key Drivers of Growth for CNB Financial, Akebia Therapeutics, Mesoblast, 21Vianet Group, Old Line Bancshares, and BioSpecifics Technologies — Factors of Influence, Major Initiatives and Sustained Production |
|
|